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ABSTRACT 
 COPD is a leading cause of morbidity and mortality worldwide. Currently 
ranked as 4th leading cause of death worldwide.  
Objective: 
 This study was aimed to evaluate the incidence of cTnT elevation in COPD 
exacerbation patients and to see if cardiac troponin T has prognostic significance 
during an acute exacerbation of COPD.  
Design: 
 Prospective study  
Participants: 
 Sample of 50 adult patients (both male and female) admitted to Government 
Rajaji Hospital, Madurai with signs and symptoms of acute exacerbation of COPD.  
Methods: 
 Blood samples for cTnT were measured on admission and 24 hrs later using 
quantitative assay by ELISA method. Levels above 0.017 µg / L were taken as 
positive. Demographic data, history & symptoms were recorded. Clinical 
examination & investigations were done on each patient. 
Results: 
 19 patients had elevated cTnT levels. They were divided into two groups, 
group 1 included patients with cTnT positive, group 2 with cTnT negative. All 
patients had increased breathlessness. Majority was males, M: F = 11.5: 1. 58% 
were current smokers.  Mean duration of COPD was high (6.42yrs) in group 1 as 
well as mean SpO2 was 75% (low) in group 1. RA, RV dilation & severe 
pulmonary hypertension were higher in group 1. 
 cTnT elevation significantly correlated with ICU admission, need for 
ventilator, ICU & hospital stay duration.  
Conclusion: 
 cTnT is elevated in  significant subset of patients with COPD exacerbation. 
Among them, COPD duration was high, mean SpO2 was low. It was an 
independent predictor of need for ICU admission and ventilator support. 
Significant difference in length of stay in ICU (or) hospital was found among two 
groups. It can be used as marker to identify patients at higher risk at the time of 
admission.  
KEY WORDS: 
 COPD (chronic obstructive pulmonary disease) 
 Cardiac Troponin T (cTnT) 
 Exacerbation  
 Corpulmonale 
 FEV1 (Forced expiratory volume at one second) 
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INTRODUCTION 
COPD is a leading cause of morbidity and mortality worldwide. 
Currently ranked as 4th leading cause of death worldwide, it represents an 
important public health challenge that is both preventable and treatable.  
The burden of COPD is projected to increase in coming decades 
due to continued exposure to COPD risk factors and the aging of the 
world’s population. 
World Health Organization (WHO) predicts that it will become the 
third leading cause of mortality by 2020; owing to decrease in cardiac 
diseases and stroke over the period 1970–2002, but that of COPD doubled 
over the same period. It is also associated with significant economic 
burden.  
COPD often coexists with other comorbidities which may have a 
significant impact on its prognosis. Cardiovascular diseases, osteoporosis, 
lung cancer, diabetes, metabolic syndrome and depression are among a 
few of them. 
Cardio vascular disease is a major comorbidity in COPD patients 
and probably the most frequent and most important coexisting illness as 
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these conditions have many risk factors in common like age, male sex, 
cigarette smoking, although its actual prevalence is unknown.  
Many factors lead to an acute exacerbation, of which bacterial or 
viral infections are most common, however in many patients the 
underlying cause remains unrecognised, of which acute LV dysfunction 
may be one. Its vice versa also holds true that an acute exacerbation, 
whether or not with a history of corpulmonale, has an increased cardiac 
burden, but prompt identification remains difficult because of non-specific 
symptoms and signs, and ECHO is not always feasible to recognise it. 
However identifying these patients may influence treatment and outcome 
for many of them. Thus biomarkers like cardiac troponins which can be 
measured by a simple test and are widely available can help us identify 
these patients. 
This study was aimed to see if cardiac troponin T(cTnT) has 
prognostic significance during an acute exacerbation of COPD. 
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AIMS AND OBJECTIVES 
1. To evaluate the incidence of cTnT elevation in patients admitted 
with acute exacerbation of COPD. 
2. To study the association of elevated cTnT with 
(i) Mortality 
(ii) Need for and duration of invasive/non-invasive ventilation. 
(iii) Length of stay at the hospital. 
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CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
This disease is characterized by limitation of airflow that is 
progressive and not completely reversible. It is associated with increased 
chronic inflammatory response in the airways and lungs to exogenous  
irritable  particles and gases.  
Type of COPD are: 
- Emphysema  
- Chronic bronchitis.  
Emphysema : 
Condition defined as destruction and enlargement of distal airways 
(alveoli of lung).  
Chronic bronchitis : 
This is clinically definable condition mainly with long standing 
cough and sputum production (Phlegm).  
Chronic cough for three months duration in each of two consecutive 
years in a patient (among them other causes for long standing cough 
should be excluded).  
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Small airway disease:  
It is characterized by narrowing of small airways.  
Chronic airway obstruction is needed to diagnose a condition 
COPD. 
STRUCTURE AND FUNCTIONS OF AIRWAYS 
Conducting airways (starting from nose upto alveolus) 
communicate external environment with alveolar space.  Cross sectional 
area of airways increases rapidly from glottis (narrowest part) to  > 300cm2 
in respiratory bronchioles.  This leads to high air speed in larger airways 
(trachea and bronchi).  Patency of airways is maintained by cartilage rings 
and cough reflex.  Normal breath sounds are due to airflow turbulency in 
larynx and central air pathways. 
In small airways, structural stiffness of walls is lacking.  Here 
patency is maintained by elastic fibres surrounding alveoli.  They give 
radial traction.  Air speed is slow & silent in small airways.  Gas transport 
occurs mainly by diffusion. 
Left side, oblique fissure separates upper and lower lobes.  Right 
side, transverse fissure divides upper and middle lobes, oblique fissure 
separates middle and lower lobes. 
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Each lobe is comprised of > 2 bronchopulmonary segments.  This 
is nothing but, lung tissue with main branch of each lobar bronchus. 
There are 10 broncho pulmonary segments on right side & 9 on left 
side. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structure of Tracheobronchial Tree 
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ACINUS 
This is gas exchange unit in lung.  It composed of respiratory 
bronchioles (which are branching) and alveolar spaces.  Here, contact 
between filtered air and pulmonary capillaries occurs.  And also oxygen 
uptake and excretion of CO2 into lung tissues occur.   Lining of alveolar 
spaces are flattened epithelial cells called Type 1 pneumocytes and few 
cuboidal cells (Type 2 pneumocytes). Type 2 cells produce surfactant. Its 
main content is phospholipids, it reduces surface tension and prevent the 
collapse of alveoli during expiration.  Type 2 cells can divide & 
reconstitute type 1 cells after lung injury. 
Figure 2 : Structure of Acinus 
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Distribution of blood circulation and ventilation in lungs is mainly 
determined by gravity.  Major part of perfusion and ventilation going to 
dependent part only.  Hypoxia causes constriction of pulmonary arterioles, 
CO2 in airway dilates bronchi.  These are useful to maintain ventilation – 
perfusion match in pulmonary segments. 
Diseases that affect ventilation locally causes entry of desaturated, 
(CO2 loaded blood) into pulmonary veins.  This leads to arterial 
hypoxemia. Compensatory increased ventilation within remaining normal 
lungs increases excretion of CO2 thereby arterial CO2 come to normal 
level.  But this will not correct hypoxemia (or) increase oxygen uptake.  
Resultant form of blood gas abnormality is “hypoxia and normocapnia”, 
this is also called ‘Type 1 respiratory failure’. 
Some causes are 
ACUTE  
• Asthma (acute)  
• Pneumonia  
• Pneumothorax  
• Pulmonary edema  
• Lobar collapse  
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• Pulmonary embolism 
• ARDS. 
CHRONIC 
• Emphysema 
• fibrosis of lung 
• Right to Left shunt 
• Brain  stem lesion. 
Severe and diffuse ventilation, perfusion mismatch leads to 
combination of hypoxia and hypercarbia, otherwise called “Type 2 
respiratory failure”.  Here normal lung is insufficient to correct elevated 
CO2. This also results from diseases that reduce total lung ventilation. 
The causes include not only lung diseases, also any diseases 
affecting neuromuscular mechanism of ventilation. (eg) brain injury, 
polyneuropathies, poisoning with  narcotics, myopathies. 
Diseases which affect alveolar spaces and capillary membranes 
{destruction (or) thickening of alveolar capillary membranes} directly 
impair diffusion of gases.  eg. Fibrosis (or) emphysema. 
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CAUSES OF TYPE 2 RESPIRATORY FAILURE 
ACUTE  
Acute severe asthma   
Upper airway obstruction  
Narcotic drugs       
Acute COPD exacerbation              
Acute neuropathies / paralysis  
Fail chest injury 
CHRONIC 
COPD 
Kyphoscoliosis 
Sleep apnoea 
Myopathies / muscular dystrophies  
Ankylosing spondylitis. 
     Pulmonary circulation is low pressure system.  This can accommodate 
more increase in blood flow that occur during exercise with raising 
pressure. Pulmonary hypetension occur, 
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• When pulmonary vessels get obstructed by thrombus 
• When destroyed by emphysema 
• When destroyed by interstitial inflammation (or) fibrosis 
Long standing pulmonary hypertension 
Hypoxia and hypercapnia 
Generalized water and salt retention (corpulmonale) 
Elevated JVP and peripheral oedema. 
LUNG DEFENSES 
UPPER AIRWAY DEFENSES 
In nose, nairs trap large particles in inspired air, small particles are 
disposed by ciliated columnar epithelium in septum and turbinates 
towards oropharynx.  At the time of cough, forced expiration against 
closed glottis causes increase in intrathoracic pressure, then it is released 
suddenly and in explosive manner.  Posterior tracheal wall is flexible, it is 
pushed inwards due to high pressure.  This decreases cross sectional areas 
and increases airspeed to produce effective expectoration.  Larynx like 
sphincter, protect the airway during vomiting and swallowing. 
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LOWER AIRWAY DEFENSES 
Immune system (both innate and adaptive) is important to maintain 
sterility, structure and functions of lower airways. 
Innate immune defense 
It is characterized by many nonspecific defense mechanisms.  
Inhaled particles are trapped by airway mucous and disposed by cilia over 
mucosal epithelium.  Cigarette smoking causes increase in respiratory 
mucous secretion and it decreases (or) impair mucociliary clearance.  This 
leads to increased risk of lower airway infections like pneumonia. 
Defective muociliary function is a key factor in several diseases, 
which includes Kartagener’s syndrome, young’s syndrome and primary 
ciliary dysfunction.  These conditions are characterized by recurrent 
respiratory infections and bronchiectasis. 
Airway secretions consist of many substances includes 
antimicrobial peptides, antioxidants and antiproteinases.  These are 
responsible for opsonisation and bacterial killing, and also important to 
regulate proteolytic enzymes secreted by inflammatory cells.  Neutrophil 
elastase enzyme is regulated by α1antiproteinase called α1 antitrypsin.  Its 
deficiency leads to development of premature emphysema. 
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Cells 
Macrophages - these are main phagocytes, engulf organic dusts, 
microorganisms and other particulate matter.  Asbestos (or) silica are 
inorganic substances which destroy and causes necrosis of macrophages 
leads to release of proteolytic enzymes, which results in parenchymal 
damage. 
Neutrophis are low in airways, but pulmonary circulation consists 
marginated pool of neutrophils, so these are easily recruited in response to 
bacterial infection. 
Eosinophils, natural killer cells and mast cells are other cells 
involved in innate immune response. 
Adaptive immune response 
This is characterized by specific response and development of 
memory.  Dendritic cells in lungs promote antigen presentation to 
lymphocytes (T & B cells). 
CD4 T cells stimulate B lymphocytes to produce antibodies  
(immunoglobulins)  that neutralise bacterial toxins and initiate the 
processes like opsonization and killing of microbes by phagocytosis.  Th2 
CD4 cells promote IgE formation that leads to allergy. 
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    Both of these (innate and adaptive) immune responses are            
co-ordinated by many cytokines which are important in initiating, 
terminating and regulation of the responses and coordinating the repair 
processes.  
EPIDEMIOLOGY 
COPD is one of the important cause of death worldwide. It occupies 
fourth leading cause of mortality. It is main cause of morbidity also and 
results in economic and social burden.  
Because of continued exposure to risk factors of COPD and 
increased life expectancy, prevalence of COPD are expected to increase 
in coming decades.  
65 million people have severe form of COPD (moderate to severe) 
based on WHO estimate in 2005, more than 3 million persons died of 
COPD, and it accounts to 5% of all death worldwide. It is known that 
approximately 90% COPD mortality occurs in developing countries (low 
to middle income countries). 
   Mortality due to COPD is expected to increase in next 10 years 
by more than 30% unless immediate action is taken to control risk factors, 
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mainly tobacco use. COPD becomes the third leading cause of death from 
sixth place globally in 2020 according to various estimates.  
 1990 2020 
 
Ischemic heart disease 
Cerebro vascular disease 
Lower respiratory infection  3rd 
Diarrhoeal disease 
Perinatal disorders 
COPD                          6th 
Tuberculosis 
Measles 
RoadTrafficAccidents 
LungCancer 
 
Figure 3: Worldwide mortality 1990-2020 
RISK FACTORS OF COPD  
Relation between genetic susceptibility and exposure to 
environmental stimuli play major role in pathogenesis of COPD. Although 
cigarette smoking is important COPD risk factor, consistent evidence 
from various epidemiological studies demonstrate that non-smokers may 
also develop chronic obstruction of airways.  
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Host factors:  
i. Age  
ii. Genetic factors 
iii. Asthma  and  airway  hyperresponsiveness 
Exposures: 
• Smoking  
• Occupational exposures 
• Environmental pollution  
• Social – economic status.  
• Recurrent respiratory infections (lower airway) 
• Childhood illnesses.  
• Diet.  
1. Cigarette smoking : 
This is one of main risk factors of COPD, various longitudinal 
studies demonstrated that inverse relationship between intensity of 
cigarette smoking and volume of air exhaled in the first second of forced 
expiration (FEV1). 
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Increased intensity of smoking leads to accelerated decline of 
FEV1. Intensity of smoking expressed in pack years (This is calculated as 
number of packets of cigarettes smoked per day multiplied by number of 
smoking years).  
This relationship is responsible for increasing prevalence of COPD 
with increasing age.  
Higher smoking rate among males in the reason for higher COPD 
prevalence among them. 
Various environmental and genetic factors contribute to effects of 
smoking on COPD development. Cigar and pipe smoking are associated 
with inhalation of low doses of tobacco by products compared to cigarette 
smoking.  
2. Environmental pollution : 
Indoor pollution : 
For cooking, heating and other household needs, many people 
worldwide use coal and biomass for energy source. In developing 
countries, increased prevalence of COPD among non-smoking women is 
due to biomass fuel for cooking. This is estimated to kill 2 million children 
and women each year.  
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Outdoor pollution : 
Relationship between outdoor pollution and development of COPD 
is unclear. But some studies reported that respiratory pathology is more in 
people living in urban areas when comparing to rural areas. This is mainly 
due to pollution of air from fossil fuel combustion. Source is motor vehicle 
emissions in cities.  
3. Occupational exposure :  
Exposure to dusts and fumes at working place is related to 
respiratory symptoms and airflow limitation. Specific occupations like 
coal mining, gold mining, textile dust (eg) cotton are considered as risk 
factors for COPD. A recent study demonstrated significant relation 
between coal mine dust exposure and development of emphysema in both 
smokers and non-smokers.  
4. Social economic status : 
There is inverse relationship between social economic status and 
development of COPD. This is related to air pollution, crowding, 
infections and poor nutrition etc.  
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5. Respiratory infections : 
Respiratory infections are most important causes for COPD 
exacerbations. But relationship between childhood and adult respiratory 
infections and development of COPD is unclear.  
Host Factors : 
1. Genetic factors : 
Development of airflow limitation among smokers is largely 
variable. Alpha 1 antitrypsin deficiency is one of the main genetic risk 
factor for development of COPD. Other genetic causes also present.  
α1 antitrypsin deficiency : 
S allele – involves α1AT level in slightly reduced range.  Z allele – 
involves severely reduced levels of α1 AT.  M allele – is related with 
normal levels of α1 AT. This is common presentation. 
    Incidence of severe α1 AT deficiency among COPD patients is  
1-2%, these patients mostly develop COPD at early age. Measurement of 
serum immunologic level of α1 AT is the commonly used laboratory test 
to screen α1AT deficiency. 
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Piz is defined as patients with 2 Z alleles (or) one Z and one null 
allele. This is the common form of severe α1 AT deficiency.  
Cigarette smoking has major influence on variations of pulmonary 
functions among Piz patients. Combination of severe α1AT deficiency and 
cigarette smoking causes development of COPD at early age. Similarly 
male sex and asthma are important risk factors of COPD among Piz 
individuals.  
Treatment for severe α1 AT deficiency is available, with that is 
infusion therapy of α1AT weekly. Other genes associated with COPD 
development are minor allele of MMPI2 and portion near the hedge hog 
interacting protein gene, some genes on chromosome 15. 
2. Age and sex : 
COPD prevalence raises as age increases, it is common after 40 yrs. 
More prevalent in men because of changing smoking pattern. Its 
prevalence increases in women also.  
3. Airway hyperresponsiveness : 
Various studies compared airway at starting of study and gradual 
fall in pulmonary function later. This demonstrated that airway 
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hyperresponsiveness is important factor for further decline in pulmonary 
function and risk factor for development of COPD.  
PATHOPHYSIOLOGY: 
Changes occur with COPD development are 
• Gradual reduction in forced expiratory flow rate.  
• Elevation in residual volume, residual volume and total lung 
capacity ratio.  
• Unequal distribution of ventilation.  
• Ventilation – perfusion mismatch.  
 
Airflow limitation (or) obstruction : 
This is demonstrated by spirometry  with parameters include FEV1 
and FVC. COPD patients have decreased ratio of FEV1 / FVC. This 
decreased FEV1 in COPD rarely show large response to bronchodilator 
inhalation.  
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Hyperinflation : 
Air trapping is the common finding in COPD patients. This is 
reflected by increased residual volume and elevated ratio of residual 
volume to total capacity of lung. These things are routinely measured by 
pulmonary function testing.  
Hyperinflation of chest leads to preservation of maximum 
expiratory flow of air by decreasing airway resistance.  
Adverse effects of hyperinflation : 
Flattening of diaphragm leads to decrease in the space of contact 
between abdominal wall and diaphragm, restriction of rib movements, 
defective generation of inspiratory pressure.  
Gas exchange : 
FEV1: reduction of its value to <50% of predicted -> will decrease 
PaO2. 
Reduction of FEV1 to <25% of predicted, will increase PaCO2.                              
        This causes development of pulmonary hypertension 
Corpulmonale and right ventricular failure. 
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PATHOLOGY: 
Exposure to cigarette smoke affect all airways of lungs. Large 
airway changes leads to symptoms like cough and expectoration of 
sputum. Small airway changes are reason for alteration in physiological 
parameters. Both these problems occur in patients with COPD.  
Large Airway : 
Enlargement of mucous glands and hyperplasia of goblet cells 
resulting from cigarette smoking leads to symptoms [cough and sputum 
production]. But this does not lead to airway obstruction. Squamous 
metaplasia may occur in bronchial wall. This is important risk factor for 
carcinoma development and mucociliary dysfunction. Smooth muscle 
cells hypertrophy also occur in COPD patients. Airway infections -> lead 
to influx of neutrophils -> purulent sputum production & generation of 
neutrophil elastase (one of the important secretogogues).  
Small airways : 
Small airways with diameter ≤ 2mm are major site of airflow 
resistance. Changes occur in COPD are metaplasia of goblet cells, 
mononuclear cells infiltration, smooth muscle cells hypertrophy. These 
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alterations lead to airway lumen narrowing by means of fibrosis, wall 
edema, increased mucous productions and cellular infiltration.  
Decreased surfactant leads to increase in alveolar surface tension 
and collapse. Destruction of airways (due to proteolytic substances) occur 
from mononuclear inflammatory cells infiltration.  
Lung parenchyma 
Emphysema is defined by destruction and dilatation of airways 
involved in gas exchange (alveoli, ducts, respiratory bronchioles). 
Changes in airway spaces are perforation and obliteration of  air spaces 
due to coalescences of small air spaces into abnormal and enlarged spaces. 
Macrophage accumulation in small air spaces is common in smokers.  
Emphysema : 
Pathologic types are centriacinar and panacinar emphysema.  
Centriacinar emphysema is commonly associated with cigarette 
smoking and it involves enlargement of respiratory bronchioles initially. 
This type is prominent   in upper lobes of lungs and superior segments of 
lower lobes.  
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Panacinar emphysema involves abnormal enlargement of air spaces 
evenly distributed along whole acinar units. This type is commonly 
associated with α1 antitrypsin deficiency and involves lower lobes usually.  
Pulmonary vasculature : 
Chronic hypoxia leads to pulmonary vasoconstriction which 
produces changes in vessels like intimal hyperplasia and smooth muscle 
hypertrophy.  
PATHOGENESIS 
Limitation of airflow way is the most important physiological 
change in COPD.  It happens as a result of both emphysema and small 
airway obstruction.  Development of fibrosis around small airways is 
important feature in small airways obstruction.  Accumulation of collagen 
occur surrounding airways in the setting of raised collagenase activity. 
Pathogenesis of development of emphysema constitutes events that 
are interrelated with each other. 
i. Long standing exposure to cigarette smoke leads to accumulation 
of inflammatory cells in terminal air spaces. 
ii. Release of elastolytic enzymes (Proteinases) causes extra cellular 
matrix damage in lungs. 
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iii.  Oxidative stress and detachment extracellular matrix from cells 
lead to structural death of cells. 
iv. Air space enlargement occurs due to insufficient repair of 
extracellular matrix components like elastin.  
• Elastase and Antielastase  Hypothesis 
Elastin is major component forming elastic fibres.  This is stable 
component, most important for maintaining integrity of lung.  According 
to this hypothesis, balance between elastin degrading substances  
(enzymes) and substances inhibiting their activity (inhibitors) determines 
pulmonary tissue’s susceptibility to destruction, that leads to enlargement 
of air spaces.  Based on this hypothesis, patients with deficient α1AT 
(serine proteinase inhibitor) were more likely to develop emphysema than 
others.  As well as introduction of elastase enzyme into an experimental 
animal leads to development of emphysema. 
Other factors identified in the pathogenesis are network of 
inflammatory and immune cells and other proteinases. 
• Inflammation and proteolysis of extra cellular matrix: 
Macrophages normally present in lower air spaces.  During 
exposure to oxidative substances from smoke particles, these 
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macrophages get activated.  This leads to production of chemokines and 
protein lysing substances called proteinases.  These recruit other 
inflammatory cells also. 
Oxidant particles from smoke 
Histone deacetylase -2 inactivation 
Acetylated chromatin with nuclear factor κB sites 
Transcription of substances (cytokines and matrix metalloproteinases). 
Accumulation of neutrophils. 
CD8 cells also accumulated in airspaces, this leads to release of 
protein 10,that in turn causes production of elastase from macrophages. 
(matrix metalloproteinase 12). 
These matrix metalloproteinases along with serine proteinases 
(important among these is neutrophil elastase) work combindly and causes 
degradation of other’s inhibitors, this finally leads to destruction of lung 
tissue. 
       Autoimmune mechanisms are also involved in the pathogenesis 
of COPD.  This was recently identified. In COPD subjects, levels of            
B lymphocytes and lymphoid follicles are high, especially in patients with 
advanced disease. Antibodies are identified against elastin. 
28 
 
 IgG autoantibodies present in some cases, they bind strongly to 
respiratory epithelium and responsible for cytotoxicity. 
Cigarette smoking leads to disruption of cilia from respiratory 
epithelial cells and impairment of phagocytosis by macrophages.  These 
changes make the airway susceptible to bacterial infections and 
recruitment of neutrophils 
 
CELL DEATH         
                              Inflammation and cigarette smoke 
Elevated oxidative stress 
Cell death 
Macrophage uptake of apoptotic cells 
Production of growth factors 
Arrests inflammation 
 
Cigarette smoking affects repair process by inhibiting apoptotic 
cells uptake by macrophages. 
Repair 
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INEFFECTIVE REPAIR 
Repair of damaged air spaces by adult lung is limited only. 
• Process called septation may be reinitiated (this is responsible for 
formation of alveoli during development). 
• Efficacy of stem cells to regenerate lung tissue (this is under 
investigation only). 
• It is difficulty to fully regenerate extra cellular matrix. 
CLINICAL SYMPTOMS OF COPD :  
• Cough  
• Expectoration of sputum  
• Breathlessness (mainly exertional)  
These are three common symptoms. Dyspnoea may be insidious. 
Patients may describe breathlessness as increased breathing effort, air 
hunger, sometimes gasping. These are elicited by proper history taking. 
Activities with arm work mainly above shoulder level are difficult with 
COPD patients. In later stages, it is difficult to perform simple works of 
daily living also.  
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Worsening of airway obstruction is associated with more frequent 
COPD exacerbation. 
PHYSICAL SIGNS: 
In initial stages of disease, physical examination is usually normal. 
Signs of smoking is evident in most of patients like nicotine stain over 
teeth, nails and smoke odour on physical examination, most of them show 
barrel shape chest, increased lung volumes with defective excursion of 
diaphragm (by percussion). Patients with severe disease may show use of 
accessory respiratory muscles, usually they prefer peculiar position called 
tripod position. This is to facilitate accessory respiratory muscle action 
(intercostals, scalenae and sternomastoid muscles). Patients may present 
with cyanosis. On auscultation they may have expiratory wheeze. (sign of 
prolonged expiratory phase).  
Emphysema patients are called “Pink puffers”, they are usually non 
cyanotic (pink) at rest and thin. Accessory muscles active in them. Chronic 
bronchitis patients are called “Blue bloaters”. They are heavy and blue 
(Cyanotic).  
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In later stage of disease:  
Patients may show severe wasting, loss of subcutaneous adipose 
tissue. Reasons for wasting are insufficient oral intake and raised 
inflammatory mediators like TNFα. This is poor prognostic factor in 
COPD. Some patients may demonstrate Hoover’s sign. This is paradoxical 
inward movement of chest wall (ribs) during inspiration.  
Signs of congestive heart failure may evident in patients with 
advanced disease. Clubbing is unusual in COPD patients. If it is present, 
we should exclude lung Ca in them.  
Table 1: Spirometric classification of COPD: 
Severity Post bronchodilator 
FEV1/FVC 
FEV1 Predicted 
(%) 
At risk# >0.7 ≥80 
Mild COPD ≤0.7 ≥80 
Moderate COPD ≤0.7 50-80 
Severe COPD ≤0.7 30-50 
Very severe COPD ≤0.7 ≤30 
Laboratory investigations : 
• Pulmonary function testing has major part in confirming and 
classifying COPD. Hallmark of airflow obstruction is reduction in 
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FEV1 and FEV1/FVC ratio. Lung volumes increase with worsening of 
disease, this leads to increase in lung parameters like residual volume, 
functional residual capacity and total capacity of lung. In emphysema, 
destruction of small airways and alveoli leads to reduction in diffusion 
capacity. Other prognostic factors of COPD are exercise capacity, body 
mass index and dyspnoea.  
• Arterial blood gas analysis may identify hypoxemia. ABG by 
measuring PCO2 (arterial) and pH give various information about acid 
base status and alveolar ventilation. This is also important in evaluation 
of patients with acute exacerbation.  
• Elevated hemotocrit is indicator of chronic hypoxemia and right 
ventricular enlargement.  
• X-ray of COPD patients may helpful in typing COPD.  
• Emphysematous changes in X-ray are hyperlucency, reduced 
parenchymal markings and bullae.  Flattened diaphragm and raised 
lung volume indicate hyperinflation of lungs.  
CT scan is useful in establishing diagnosis of emphysema. Testing 
for α1AT deficiency in all patients with COPD (or) asthma is important 
according to recent guidelines. Initial test is it´s measurement in serum. If 
it is deficient, it will require protease type determination.  
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ASSESSMENT OF DISEASE: 
The goals of assessment of COPD are to know disease severity, its 
effect on patient’s health, to determsine future course of disease like acute 
exacerbations, hospital admissions and mortality, also to guide treatment 
modality.  
GOLD guidelines use certain factors to determine risk of 
exacerbations and guide treatment. These include  
• Patient’s symptoms.  
• Past history of exacerbations  
• Forced expiratory volume at one second (FEV1)  
Severity of COPD symptoms is  assessed by  
• CAT – COPD assessment test  
• mMRC - modified medical research council.  
In previous 1 yr, number of acute exacerbations can be used to 
determine future events. 
• History of 0 (or) 1 exacerbation in past 1 year → low risk group 
for future exacerbation.  
• ≥ 2 exacerbation in past 1 year → grouped as high risk.  
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Lung dysfunction severity is assessed based on FEV1 value after 
broncho dilation using GOLD guidelines. Stages in GOLD classification 
are at risk to very severe disease.  
Group A patients  
Low  risk group, GOLD stage 1 (or) 2 [mild (or) moderate limitation 
of  air flow] and / or  0 (or) 1 acute exacerbation  per 1 yr, mMRC grade 
0-1 (or) CAT score <10. 
Group B patients  
Low risk category, stage 1 (or) 2 in GOLD classification, and / or 
0-1 exacerbation of disease per year and mMRC grade ≥2, (or) CAT ≥10.  
Group C patients  
High risk group, GOLD stage 3 (or) 4 [severe (or) very severe 
airflow obstruction] and/or ≥2 exacerbations per year and mMRC grade 
0-1 or CAT score < 10. 
 Group D Patients 
High risk category, GOLD staging 3 (or) 4 and / or ≥2 acute 
exacerbation of disease and mMRC grade ≥2 (or) CAT Score ≥10. 
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TREATMENT  
Stable COPD :  
i. Abstinence from smoking.  
ii. Treatment with oxygen for longstanding hypoxemic patients  
iii. For emphysema cases, surgeries involving lung volume reduction.                         
Only, treatment with inhaled corticosteroids may affect the death 
rate. All other treatment modalities are mainly aimed at improve  
patient’s symptoms  and decrease the acute exacerbations  
frequency.  
Smoking cessation : 
This is most important and effective intervention to decrease the 
risk of COPD development as well as to arrest the progression of disease.  
Pharmacological interventions available to stop smoking are  
• Bupropion (antidepressant drug)  
• Replacement treatment with nicotine [Chewing gum, patches 
(transdermal), nasal spray and inhalers are available forms.]  
• Nicotinic acid receptor agonist and antagonist drug ─ varenicline.  
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Most of the occupationally acquired respiratory problems can be 
controlled through variety of methods, mainly focused at decreasing the 
burden of inhalation of particles and gases. Decreasing the risk from 
environmental air pollution is difficult and it needs combination of public 
policy and protective measures taken by individual patients.  
Bronchodilators : 
• Treatment with bronchodilators are key to symptoms management 
in patients with COPD.  
• Inhalation route of therapy – preferred than parentral route as side 
effects are low.  
• Drugs like β2 agonist, theophylline and anticholinergics are used. 
Combination (or) choice of individual therapy depends on 
availability of drug and patient’s response to drug (like control of 
symptoms and side effects).  
Anticholinergic drugs : 
Drugs like ipratropium bromide and Tiotropium are used.  
Ipratropium – produces symptom relief and causes acute increase 
in FEV1value.  
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Tiotropium is long acting drug. It gives symptomatic relief and 
decreases the frequency of exacerbation.  
Some studies demonstrated that mortality rate is reduced in 
tiotropium treated patients compared to ipratropium treated group, but this 
didn’t approach statistical significance. Side effects are lower with inhaled 
anticholinergic drugs.  
Beta 2 Agonists : 
These drugs give symptomatic relief. Side effects are increase in 
heart rate and tremor.  Long acting drugs like salmeterol (inhalation form) 
is much beneficial as ipratropium bromide. More convenient compared to 
short acting β2 agonist.  Combination of β2 agonists and inhaled 
anticholinergic drugs demonstrated additional benefit than single agent 
alone.  
Treatment with inhalational steroids reduce the frequency of 
exacerbation by nearly 25%. But its effect on mortality rate is being 
controversial.  Side effects are candidiasis in orophrynx and loss of bone 
mineral density. They are mainly useful in COPD patients with more 
frequent disease exacerbation and those who show significant   
improvement (or) reversibility of symptoms with inhalational 
bronchodilators.  
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Oral steroids : 
Chronic therapy with oral steroids for COPD patients is not 
advisable, because risk / benefit ratio is not favourable. Long standing 
steroid treatment is related with important side effect like osteoporosis, 
increased infection risk, impaired glucose tolerance and cataract.  
Theophylline : 
Moderate improvement in vital capacity and air flow rate during 
expiration occur with theophylline. In severe COPD patients, it produces 
mild improvement in O2 and CO2 levels (arterial). Side effects are nausea, 
tremor and increase in heart rate. To minimize theophylline toxicity, 
monitoring it’s level in blood is important.  
Oxygen  
 O2 therapy is the only pharmacological measure demonstrated to 
decrease the death rates among COPD patients unequivocally. Resting 
hypoxemia is defined as O2 saturation ≤ 88% at rest (or) < 90% with signs 
of Corpulmonale (or) pulmonary vascular hypertension.  Among these 
patients, use of O2 therapy  has beneficial effect on mortality rate. Benefit 
depends on (or) propotional to O2 usage time (hours or days). Oxygen 
therapy available as portable systems. 
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Other drugs : 
N- acetyl cysteine – it is mucolytic and has antioxidant properties. 
It’s effect on improving lung function and decreasing exacerbation is 
doubtful.  
α1AT therapy -  it is available in intravenous  form.  Some studies 
(trial), not clearly demonstrated its effect on reducing decline of lung 
function.  Patient with serum level of α1AT 11 µm requires α1 AT therapy. 
Severe α1 AT deficiency state with normal lung function does not require 
α1 AT therapy.  
Non Pharmacological treatment:  
Vaccination with influenza vaccine (yearly once) and 
pneumococcal (Polyvalent) vaccine is important in COPD Patients. This 
is to reduce infections with these organisms, thereby exacerbations.  
Pulmonary Rehabilitation : 
This program includes, education of COPD patients and 
cardiovascular conditioning. It improves patient’s life quality, 
breathlessness, exercise tolerance and decreases hospitalisation.  
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Lung volume reduction surgery : 
This is applied in emphysema patients. Patients with severe pleural 
disease, pulmonary artery   hypertension (>45 mmHg), heart failure, other 
comorbid problems are excluded. Patients with diffuse emphysematous 
lesions, FEV1 level <20% of normal value, Diffusion Capacity of Lung 
for carbon monoxide <20% normal are poor candidates for surgery.  
This surgery gives significant benefit in terms of symptoms and 
mortality in some patients of emphysema. Those with emphysematous  
changes mainly in upper lobes and reduced exercise tolerance  after 
rehabilitation  are commonly  benefit from this surgery.  
Lung transplantation: 
COPD is the second common indication for lung transplantation.  
Criteria for selection of candidates are  
• Age < 65 yrs.  
• Severe disease and suffering even after maximum 
pharmacological treatment.  
• Absence of comorbid problems.  
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Diffuse emphysematous lesions and pulmonary vascular 
hypertension are not contraindication for this procedure.  
 
 
Figure 4: Overview of management of COPD patients 
according to stage  
 
 
 
COPD EXACERBATION:  
Acute exacerbations are important feature of natural course of 
disease process.  Average number of acute exacerbations per year is 1.3.  
Exacerbations are characterized by episode of symptoms – 
increased breathlessness, cough and change in sputum amount and 
character. Other features like fever, sore throat and myalgia may be 
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present. Airflow limitation and exacerbation episodes are directly related. 
When airflow obstruction severity increases, exacerbation frequency also 
will increase.  
During each exacerbation episode, we should assess the severity of 
disease at that time, cause for exacerbation (precipitating factor) and 
therapeutic options.  
COPD exacerbation are costly and morbid event. They severely 
affect the patient’s life quality. It may lead to permanent loss of pulmonary 
function. Hospital admissions due to disease exacerbations occupy major 
part of economic cost. Mortality due to acute exacerbation reach upto 10% 
and 25% of patients may require ICU admissions and ventilator support. 
Prevention of exacerbation, early identification and effective management 
are most important to decrease the burden of COPD.  
Precipitating factors : 
A variety of precipitating factors may cause final process of 
increased airway inflammation and symptoms. Among these, infection of 
airway and air pollution are commonly identifiable factors. Bacterial 
infections are important one, but viral infections are also present in 1/3 of 
disease exacerbations.  No cause is found in 20-35% of cases.  
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Despite of common contribution from bacterial infections, 
prophylactic antibiotic treatment has not show significant benefit against 
exacerbations.  
Treatment with inhalational steroids decreased exacerbation 
frequency by 20-35% in most studies. Oral glucocorticoids (chronic 
therapy) are not advisable for prophylaxis.  
Influenza vaccine has some role in decreasing exacerbations in 
COPD. 
LV dysfunction may also a cause for disease exacerbation, as well 
as during acute exacerbation of COPD, cardiac burden increases, LV 
dysfunction also occurs. But its identification is difficult due to non 
specific signs and symptoms. ECHO evaluation is not possible during 
exacerbation. Recognizing these patients may affect the treatment and 
prognosis of them. So biomarkers such as cardiac specific troponins can 
be useful to recognize these patients. It is measured by simple and easily 
available laboratory tests.  
Assessment of exacerbation : 
We should assess the severity of disease exacerbation and also 
severity of disease (COPD). If any one of components is severe, patient  
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will  need in hospital treatment.  History is essential to assess the severity 
of symptoms like degree of breathlessness, about fever, quality and 
quantity of sputum and other symptoms like chills, rigor, diarrhea, nausea 
and vomiting.  
On physical examination, attention should be given for certain signs 
(eg) increase in heart rate and respiratory rate, over action of accessory 
muscles of  respiration, cyanosis, ability to talk complete sentences, 
patient’s neurological status.  
Chest examination of patients should focus certain things like focal 
findings, symmetry of chest, added lung sounds, degree of airflow both 
sides and  paradoxical chest and abdominal movements.  
X-ray chest is needed in severe COPD patients with more distress. 
25% of those patients have features of pneumonia (or) congestive cardiac 
failure in X-ray.  
Arterial – blood gas analysis is required for late stage COPD, those 
with hypercarbia history, alteration in mental status and severe 
exacerbation.  Hypercarbia (that is PaCO2 > 45mmHg) has significant 
effect on treatment. 
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Indications for hospital admission:  
Around 50% of disease exacerbations are mild (even not consulted 
to physicians).  Mortality from acute COPD exacerbations raises with 
development of respiratory acidosis, in patients with other severe 
comorbid problems and those requiring ventilatory support.  
1. Marked increase in intensity of symptoms  
2. Underlying severe COPD  
3. Onset of new signs like cyanosis, peripheral edema.  
4. Failure of  response to initial medical management.  
5. Presence of other severe comorbid conditions.  
6. Frequent exacerbations.  
7. Elderly age.  
8. Insufficient home support.  
9. Severe hypoxemia, hypercarbia and respiratory acidosis.  
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Treatment of acute COPD exacerbation 
 
 
 Bronchodilators : 
Usually patients are managed with inhalational β2 agonist and  
anticholinergic  drugs either separately (or) in combination form. 
Administration frequency depends on disease severity. Usually treatment 
given with nebulised therapy. This form of therapy is easier to give in 
elderly patients and during severe respiratory difficulty.  We can add   
methylxanthines to this regimen.  
Antibiotics : 
COPD patients are frequently infected with potential 
microorganisms peculiar for respiratory system. Identification of specific 
bacterial species responsible for disease exacerbation is difficult. 
Common bacteria encountered in COPD patients with exacerbation are 
pneumococcus, moraxella catarrhalis and Hemophilus influenzae. Other 
agents like mycoplasma pneumoniae, Chlamydia are present in some 
cases. Selection of antibiotics based on following two things  
i) antibiotic agent susceptible to  above  mentioned  organisms 
ii) patient’s condition.  
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Glucocorticoids  
Treatment with glucocorticoids during hospital admissions, 
decreases the hospital stay duration, faster recovery and it decreases the 
frequency of further exacerbations (or) relapse for 6 months period. There 
is no significant difference in benefit between 2 weeks steroid therapy and 
8 weeks course of treatment with steroid. Dose of oral prednisolone 
according to GOLD guidelines is 30-40mg per day to 10-14 days. 
Hyperglycemia is commonly encountered complication of steroid therapy.  
Oxygen : 
Aim of O2 supplementation is to maintain arterial O2 saturation 
≥90%. Some studies showed that O2 therapy does not affect minute 
ventilation in patients with hypercarbia. In some of them, it may cause 
increase in PCO2. This is mainly by changing ventilation and perfusion in 
lungs.  
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Mechanical ventilation : 
If PaCO2 is more than 45mmHg, we should suggest noninvasive 
positive pressure ventilation. This is initiating factor for NIPPV. It reduces 
mortality rate sufficiently, decreases intubation need and treatment 
complications, it reduces hospital stay duration also. Contraindications for 
NIPPV are hemodynamic instability, altered mental condition, 
uncooperative patients, large amount of secretions, difficulty in clearing  
secretions, facial dysmorphism (or) trauma that    lead to difficulty in 
fitting the mask, obese person and burns. Indications for Endotracheal 
intubation and mechanical ventilation are:   
• Severe breathlessness inspite of initial intensive treatment.  
• Severe hypoxemia 
• Hypercarbia and respiratory acidosis 
• Severely altered mental condition.  
• Hemodynamic compromise.  
• Respiratory failure and arrest.  
Aim is to overcome the above mentioned problems. In ventilators, 
we should maintain sufficient time of expiration and auto PEEP.                 
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17-30% is the mortality rate among patients with mechanical ventilator  
support during that hospitalization. For elderly patients    (age >65 years) 
who got the intensive care treatment, death rate doubles in subsequent year 
to 60%. 
 
 
 
 
 
 
 
 
Figure 5: Flow-chart for the use of noninvasive positive pressure 
ventilation(NIPPV) during exacerbation of chronic obstructive 
pulmonary disease(COPD) complicated by acute respiratory 
failure. MV: mechanical ventilation; PaCO2:arterial carbon 
dioxide tension. 
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Figure 6: Management of patients in various stages of their disease 
Cardiovascular problems in COPD : 
Cardio vascular mortality is major cause of mortality in COPD 
individuals. 12-37% of COPD patients die from cardiovascular disease 
according to sin et al estimation. Common cardiovascular problems are 
cardiac failure (Right heart), acute myocardial infarction, arrhythmias, 
stroke, peripheral vascular disease. Their prevalence is more   common in 
COPD patients compared to non-COPD subjects. Several studies 
demonstrated the relation between decline of FEV1 and raised risk of  
cardio vascular disease. Patients with CAD have poor prognosis (survival) 
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during their admission for acute exacerbation. Elevated cardiac troponins 
and NT pro-BNP during exacerbation compromise patient’s 30 days 
survival. This message again to show relationship between respiratory and 
cardiovascular factors during COPD exacerbation. 
Pulmonary hypertension and  Corpulmonale.  
Pulmonary vascular hypertension (PH) with hypoxemic lung 
problems come under group III of WHO. WHO defines corpulmonale in 
1963 as right ventricular hypertrophy resulting from diseases affecting 
structure and / or functions of lungs except when these pulmonary 
alterations are due to problems that mainly affect the left side of heart (Eg.) 
in congenital heart disease.  
PH occurs as a result of many factors that includes vasoconstriction  
of  pulmonary vascular system caused by acidemia, alveolar hypoxia, 
obliteration of pulmonary vasculature from parenchymal pathology and 
increase in viscosity of blood and raised cardiac output  because of  
polycythemia  from hypoxia. Among these, most significant factor is 
hypoxia.  Alterations in airway resistance increase resistance in 
pulmonary vessels in COPD patients by raising alveolar pressure. Impact 
of airway resistance over pulmonary arterial pressure is most important 
when ventilation raises (during COPD exacerbation). In COPD patients, 
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even slight increase in airflow (eg. during minimal exercise) causes 
significant increase in pulmonary artery pressure. Alveolar hypoxia is a 
powerful stimulus for constriction of pulmonary arteries that decreases 
perfusion (to restore PCO2). Positive relationship exists between PaCO2 
and pulmonary artery pressure in patients with COPD.  
Level of pulmonary artery hypertension (even it is mild) is one of 
the prognostic predictor in COPD patients.  
 
 
Figure 7: The relation between cigarette smoke and its pulmonary 
and cardiovascular effects 
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The above picture shows various processes related with cigarette 
smoke   that causes vasoconstriction, proliferative changes in pulmonary 
arteriolar walls and vasodilation also. These effects are mainly caused by 
oxidants (which are present in smoke) that act on walls of blood vessels. 
It produces vasoconstrictors like endothelins and endothelial growth 
factor (VEGR). Smoke particles also cause vasodilation by reducing the 
bioactivity of nitric oxide. Air trapping induced hyperinflation causes   
compression of vessels   and hypoxia induced vasoconstriction occur only 
when O2 tension is very low.  
Right ventricle : 
It is low pressure chamber, it has thin wall and complaint, pumps 
stroke volume same that of left ventricle. It shares 25% stroke work due 
to normal low resistance in pulmonary vascular system. RV free wall is 
supplied by right coronary artery in systole as well as diastole. Long 
standing pressure overload leads to structural changes in RV (hypertrophy 
and dilatation), which result in systolic and diastolic dysfunction. 
Ischemia of right ventricle may occur because of inability to give adequate 
blood supply to hypertrophied right ventricle by RCA. This is partly due 
to decreased RCA to RV cavity pressure gradient   both during contraction 
and relaxation phase. This results in corpulmonale later.  
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Other cardio vascular problems: 
Recovery of heart rate after exercise is impaired in patients with 
spirometric abnormalities. The reason for this is not clear, it may be due 
to altered autonomic function related with respiratory dysfunction.  
Incidence of atrial fibrillation, congestive heart failure, 
atherosclerosis and myocardial infarction is more among COPD patients 
compared to non-COPD subjects. This is due to shared genetic and 
common risk factors like cigarette smoking, poor diet and sedentary life 
style between COPD and cardio vascular diseases.  
Many studies have demonstrated that impaired pulmonary function 
is accompanied with increased cardiovascular risk (even after adjustment 
for known risk factors of cardio vascular disease).  
Proposed mechanisms are:  
1. Systemic inflammation.  
      Systemic inflammation is increased during COPD exacerbation, due 
to circulating activated leukocytes and more inflammatory mediators. 
Causes for systemic inflammation is not clearly defined, but many 
mechanisms have proposed, these are  
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- Direct ‘Spill over’ of pulmonary inflammation into systemic 
circulation.  
- Due to the effect of hyper inflated lung  
- Tissue hypoxia.  
- Muscle dysfunction.  
- Stimulation of bone marrow.  
Systemic inflammation increases the inflammatory processes in 
atherosclerosis and thrombosis, there by increases cardio vascular risk.  
C-reactive protein (CRP) is one of the systemic inflammatory marker. Its 
level may raise in COPD patients. It is a marker of progression of 
atherosclerosis and increased mortality in COPD patients. CRP is main 
risk indicator of cardio vascular disease.  
Oxidative stress : 
Oxidative stress has major pole in the pathogenesis of 
atherosclerosis and cardiovascular disease, mainly due to its adverse effect 
on endothelial cell function (in vessels). But there are no studies available 
to assess the hypothesis that raised oxidative stress (systemic) leads to 
more cardiovascular problems in COPD patients.  
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In COPD, oxidative stress (both pulmonary and systemic) can 
occur.  
Activated neutrophils in peripheral circulation  
Release of ROS (reactive oxygen species)  
Nitrotyrosine and lipid peroxidative products. 
 (oxidative markers) in plasma.  
In COPD exacerbation, oxidative stress increases, along with 
increased systemic inflammatory response, this causes plaque instability 
and rupture. 
This may disturb fibrinolytic balance leads to thrombosis over 
ruptured area and acute coronary events.  
Activated neutrophils during acute exacerbation release more 
inflammatory mediators like IL6, TNF α, IL1β. These increase the 
permeability of cardiac myocytes, leads to apoptosis of cells.  
2. Hypoxia :  
Heart takes energy from aerobic metabolism. At rest, takes              
10-15ml of O2 per minute per 100g of tissues. This rate is higher than that 
in brain. For functioning of heart, continuous and adequate amount  
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of oxygen is necessary and it is so important. O2 is major determinant of 
genetic expression over myocardial cells. Oxygen is basic for nitric oxide 
formation and it affects vascular tone as well as tissue’s blood supply.  
During acute exacerbation of COPD, broncho constriction, 
excessive mucous production in airways and wall edema occur. These lead 
to alveolar hypoxia that in turn causes pulmonary vasoconstriction and 
hypoxemia.  
Hypoxia and tachycardia during exacerbation affects balance 
between oxygen demand and supply. This leads to myocardial ischemia. 
(mostly subendocardial).  
COPD and chronic respiratory failure are associated with 
sympathetic nervous system activation. This may be the contributing 
factor for cardiovascular morbidity and mortality seen in COPD patients. 
One of the association with COPD is decreased heart rate variability, this 
is an indicator of abnormal autonomic regulation of cardiac tissue. It 
predicts the death in older patients.  
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    Figure 8: Hypothetical mechanism for a COPD effect on 
                    cardio vascular risk 
 
TROPONINS  
Troponins are protein molecules, these form integral part of cardiac 
musculature. They occupy major role in excitation and contraction 
coupling. They are present in both cardiac and skeletal musculature. They 
are not present in smooth muscle cells. Composition of these molecules 
varies between skeletal and cardiac muscles.  
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3 types of troponins are existing.  
i) Troponin I 
ii) Troponin T 
iii) Troponin C 
Troponin I 
 Binds to actin in thin myofilaments thereby it holds troponin – 
tropomyosin complex in place.  
Troponin T  
Binds to tropomyosin, interlock them to produce a troponin – 
tropomyosin complex.  
Troponin C  
            Binds to calcium ions and produces conformational change in 
troponin I which results in separation of troponin and tropomyosin 
complex from actin filaments which exposes binding site for myosin on 
actin.  
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 Physiology of cardiac muscle contraction: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Demonstrating free and bound forms of cardiac troponin 
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Physiology of cardiac muscle contraction 
Action potential 
Increase in intracellular calcium ions 
Binding of calcium ions to troponin C 
Conformational changes in troponin I 
Separation of troponin – tropomyosin complex from actin. 
Attachment of myosin to binding site on actin 
Contraction of cardiac muscle. 
Myocardial infarction : 
It is the leading cause of death especially in developed countries, its 
incidence is increased greatly especially in patients with chronic renal 
failure and COPD. 
Definition : 
According to 2007 expert consensus document, myocardial 
infarction is defined as ‘ the detection of rise and/ or fall in cardiac 
troponins with atleast one value above the 99th percentile of upper 
reference limit (URL) utilising an assay with less than 10% coefficient 
variation at the level of detection, together with evidence of ischemia. 
Infarction was defined as any symptom of ischemia, electrocardiographic 
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changes suggestive of new ischemia, development of pathological                
Q wave in electrocardiogram (ECG) or imaging evidence of infarction.  
Sudden cardiac death (SCD) with evidence of myocardial ischemia, 
more than 3 times elevation in cardiac bio-markers in post PTCA patients 
and more than 5 times cardiac bio-marker elevation in post CABG patients 
were also included in the definition of myocardial infarction. 
Myocardial infarction usually occurs due to the rupture of 
vulnerable plaque present in epicardial coronary arteries. 
Clinical classification of types of myocardial infarction : 
There are five types, 
• Type 1 is spontaneous MI due to coronary artery plaque rupture or 
due to coronary dissection. 
• Type 2 is MI occurring due to increased oxygen demand or 
decreased supply. 
• Type 3 is sudden cardiac death (SCD) with symptoms of 
myocardial ischemia, new onset ST elevation, or left bundle 
branch block (LBBB). 
• Type 4a is associated with percutaneous coronary intervention 
(PCI). 
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• Type 4b is associated with stent thrombosis. 
• Type 5 is associated with coronary artery bypass graft (CABG). 
Diagnosis of myocardial infarction : 
Acute myocardial infarction can diagnosed from clinical signs and 
symptoms, electrocardiographic changes and estimation of cardiac bio-
markers. 
Signs and symptoms : 
The classical symptom of myocardial infarction is crushing retro-
sternal pain which may be described as squeezing or constricting type of 
pain classically radiating to left arm with impending sense of doom. The 
pain described here is similar to angina pectoris, but is more severe, lasts 
more than 20 minutes, and not relieved with rest or nitroglycerine. Pain 
gradually increased over a period of time and it is not instantaneous pain 
as with aortic dissection or pulmonary embolism. 
The chest discomfort may radiate to the neck, jaw, epigastrium, 
right arm, shoulders and back. Ischemic pain localised to epigastrium is 
often misdiagnosed for dyspepsia especially in patients with inferior wall 
infarction. 
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Diaphoresis, light headedness, acute confusion, palpitation, 
dyspnoea, fatigue, indigestion, nausea and vomiting are the associated 
symptoms given by the patients with acute myocardial infarction. 
Myocardial infarction can occur without chest pain especially in elderly, 
patients with diabetes mellitus and in post-operative patients. If the pain 
is sudden, instantaneous and is radiating to back with unequal pulses on 
examination , acute aortic dissection should be considered. 
In general, general examination findings in patients with 
myocardial infarction does not add much to the diagnosis. But it is 
extremely helpful in excluding mimickers of myocardial infarction. They 
are also useful in risk stratifying the patients and in identifying the 
impending heart failure. The initial physical findings act as a baseline, 
such that we can monitor for any complication that develop in the course 
of disease progression. 
Electrocardiography : 
ST elevation of 1 mm or more in 2 or more contiguous leads, with 
reciprocal changes in the contralateral leads is considered to be the 
definitive electrocardiographic evidence of acute myocardial infarction. 
In leads V2 and V3, ST elevation of 2 mm in men and 1.5 mm in women 
are required for diagnosis. 
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Left bundle branch block (LBBB) in the setting of symptoms that 
are typically indicative of myocardial infarction is again considered 
electrocardiographically significant. 
Estimation of cardiac bio-markers: 
Cardiac bio-markers are considered essential in the diagnosis of 
myocardial infarction even though they are not considered in the 
therapeutic flow chart. 
The following features are essential for the ideal biochemical 
marker, 
1. Present in high concentration in myocardium 
2. Absent in non-cardiac tissue 
3. Released rapidly in a linear fashion following myocardial necrosis 
4. Present in blood for a relatively longer duration to be easily 
detectable by inexpensive and universally available assays. 
Aspartate aminotransferase, total lactate dehydrogenase, and lactate 
dehydrogenase isoenzymes were used previously for detecting myocardial 
necrosis. But their wide tissue distribution limits the specificity for 
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myocardial necrosis, and therefore these tests are no longer being used in 
the evaluation of acute MI. 
1. Myoglobin : 
They are released into the blood stream following myocardial 
necrosis and are detected in blood between 1 and 4 hours. Hence they are 
considered to be the earliest markers of myocardial injury. But they are 
not cardiac specific and hence they are not routinely done for diagnostic 
workup of myocardial infarction. Their estimation may be helpful in risk 
stratification of the patient after reperfusion therapy. 
2. Creatine kinase (CK) : 
Creatine kinase (CK) is carrier protein for high energy phosphates 
present in muscle fibre. Creatine kinase-MB (CK-MB) is an isoenzyme of 
creatine kinase which is found abundant in cardiac myocyte. However, 
even CK-MB constitute 1 – 3 % of the creatine kinase in skeletal muscle. 
They are also present in small fraction in other organs like uterus, prostate, 
small bowel and diaphragm. Hence even significant elevation of CK-MB 
in the presence of injury to one of these organs is considered absurd. 
Estimation of creatine kinase is rarely helpful in the diagnosis of 
acute myocardial infarction in patients with classical chest pain and ECG 
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changes diagnostic of MI as it takes a minimum of 4 hours to get detected 
in blood and its initial normal value doesn’t exclude MI. They are neither 
used for therapeutic considerations as well. It takes 4 to 6 hours to get 
detected in serum and its level peaks at 24 hours, but the peak serum level 
is believed to occur earlier in patients undergoing successful reperfusion. 
Both CK and CK-MB get elevated in pericarditis and myocarditis, where 
there is diffuse ST-T changes as well leading on to diagnostic dilemma. 
They are helpful in assessing the size of infarct and timing of MI and not 
for the diagnosis. 
False positive raise in creatine kinase is found in skeletal muscle 
disease and trauma (eg.,rhabdomyolysis ). 
3. Troponins : 
Cardiac troponins are considered to be the gold standard and 
definitive evidence of myocardial damage and it is the class 1 indication 
for the diagnosis of myocardial infarction. They are particularly being 
useful in the diagnosis and management of unstable angina and NSTEMI 
because of their high sensitivity, easy availability and their ability to be 
used as bedside test. At present, the lag time between the critical occlusion 
and detectable elevation in serum limits its usefulness in detecting acute 
ST-elevation myocardial infarction; however, with the development of 
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high sensitive troponin T assay which can be detected within one hour of 
critical coronary occlusion may allow much early detection of myocardial 
necrosis. Also a single troponin T estimation at 72 hours will indicate the 
infarct size independent of reperfusion. 
Cardiac troponin elevation in the absence of myocardial infarction 
is found in, 
• Congestive cardiac failure 
• Myocarditis 
• Pulmonary embolism 
• Hypertrophic cardiomyopathy 
• Aortic dissection 
• Cardiac contusion 
• Drug toxicity, and 
• Acute neurological diseases. 
It can also occur due to hemolysis or assay interference with 
heterophilic antibodies. These heterophilic antibodies can cause false 
positive test result in 1 in 2000 tests done. To minimize these, non-specific 
blocking antibodies are being added to modern assays. 
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Mechanism of Troponin elevation in acute myocardial infarction : 
Among the cardiac troponins, troponin-C is expressed in both 
cardiac and skeletal muscles. In contrast to troponin-C, the amino acid 
sequences of troponin-I and troponin-T are unique to cardiac muscle and 
this difference allowed the development of rapid, qualitative assays for 
detecting troponin-I and troponin-T for detection of myocardial necrosis. 
Majority of troponins are structurally bound to the contractile apparatus 
of cardiac myocyte, but approximately 3 – 5 % of troponin-I and 6 – 8 % 
of troponin-T is free in the cytoplasm. 
After the myocyte injury, there is a biphasic raise in the cardiac 
troponins. 
• Phase 1 :  
Corresponds to the release of the cytosolic fraction of troponins. 
• Phase 2 : 
Corresponds to the gradual dispersion of myofibril bound 
troponins. 
It takes a minimum of 2 – 4 hours for the trans-mural myocardial 
necrosis to occur, even it takes longer in the presence of collaterals, 
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preconditioning and intermittent coronary occlusion. Hence they can only 
be detected 2 – 4 hours after the critical occlusion. It is recommended that 
blood samples are to be assayed both at presentation and 6 – 9 hours later 
to optimize both the clinical sensitivity to ruling in MI and specificity to 
rule out MI. It was previously believed that because of its large molecular 
weight, troponins are being cleared by reticulo-endothelial system. But 
recent evidence suggests that troponin-T is fragmented in to smaller 
molecules which are then excreted via kidneys. This explains why 
troponin T alone is elevated in case of renal failure. 
Troponin sensitivity and specificity: 
The sensitivity of troponins increases with time as dictated by 
troponin kinetics. For troponin-T sensitivity,  
At presentation = 25 – 65%, 
Between 2 to 6 hours = 59 – 90%, 
After 6 – 12 of admission = 100 %. 
For troponin-I the sensitivity,  
At presentation = less than 45%, 
Between 2 to 6 hours = 69 – 82 %, 
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After 6 – 12 hours = 100 %. 
Thus the maximal sensitivity for troponin assay will not reach 100% 
until 6 hours following myocardial necrosis. This is the reason for 
assaying troponin between 6 and 12 hours, for establishing the diagnosis 
of myocardial infarction. Unlike the sensitivity, the specificity of cardiac 
troponins does not vary significantly over time. The specificity for 
troponin-I vary between 83 – 98%, while the specificity for troponin-T 
vary between 86 – 98%. 
The negative predictive value for cardiac troponin-I, 
At presentation = 85% 
After 12 hours = 98%. 
The negative predictive value for cardiac troponin-T, 
At presentation = 88% 
After 12 hours = 99%. 
The presence of such high specificity of cardiac troponins, they are 
associated with very low false positivity rate.  This inherent property of 
cardiac troponins are being used for assessment of myocardial injury in 
patients with skeletal muscle dystrophy, myositis, crush injuries, marathon 
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runners, following electrical cardioversion, and in cases of peri-operative 
myocardial infarction. Other causes for myocardial injury are to be 
considered when there is an elevated level of cardiac troponins in absence 
of myocardial infarction. 
High sensitivity (hs) troponin assays : 
They are helping to overcome the limitations of conventional 
troponin assays for the earlier diagnosis of myocardial infarction. They 
got elevated even before 1 hour following myocardial infarction, thus 
helping to guide in further therapeutic intervention. Advances in 
immunoassay technology have resulted in multiple second generation 
troponin-I assays and fourth generation troponin-T assays. In contrast to 
troponin-T assays which are produced by the single manufacturer, 
troponin-I assays lack calibrator standardization resulting in significant 
variation in troponin-I results among different assays. 
In one study, at presentation hs-troponin I has 
Sensitivity = 90.7%, 
Specificity = 90.2%, 
Positive predictive value = 87%. 
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This demonstrates the greater diagnostic accuracy of hs-troponins 
compared to conventional assays, in particular for the patients who present 
within 3 hours of symptom onset.  The high specificity of hs-troponins 
along with negative predictive value of 97 – 98 % used to reliably rule out 
myocardial infarction. This creates an opportunity to rapidly initiate 
effective medical management, including identifying candidates for early 
coronary intervention. 
Because of the wider availabilities of hs-troponin assays, there is 
diagnostic shift from unstable angina to NSTEMI. 
Prognostic implications of cardiac troponins: 
        Troponins not only have diagnostic values, they are having 
prognostic implications as well i.e. patient with clinical evidence of 
ischemia and raised troponins have a poor prognosis compared to patients 
without raised troponins. Even patients with stable coronary artery 
disease, a small rise in hs-troponin indicates the higher incidence of heart 
failure and cardiovascular death. Recently it has been proved that peak 
level of troponins indicates the size of the infarct, and is independent 
predicator of left ventricular function, and adverse cardiac events at one 
year. There is a statistically significant rise in mortality with the rise in 
level of troponins. There is relative risk for death of 7.8 among patients 
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with peak level of troponins, inspite of adjustment for age, baseline 
variable and ST changes. 
COPD and cardiac specific Troponin T: 
Risk factors of cardiovascular diseases and cardiac comorbid 
conditions are frequent in COPD patients. It expresses the severity of 
disease exacerbation. Harvey et al found that patients with COPD 
presented with raised troponin levels were elderly people, had decreased 
oxygen saturation, and more acidotic.  Hypercapnoea is more in this 
group.  
Elevated troponin is an independent predictor for requirement of 
noninvasive mechanical ventilation and death among patients admitted 
with disease exacerbation.  
The amount of energy and requirement of oxygen for respiration 
are raised during acute COPD exacerbation. The mismatch between 
oxygen requirement and supply is one of reasons for myocardial injury 
during exacerbation.  
Left ventricular afterload is raised in relation with more negative 
intrathoracic pressure.  
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Hypoxia, hypercapnia, progressive worsening of pulmonary 
hypertension, hyperinflation of lungs, tachycardia, respiratory muscles 
fatigue -> these are the factors contributing to myocardial damage during 
COPD exacerbation period.  
Increased local as well as systemic inflammation is the main 
mechanism for myocardial injury and troponin elevation during 
exacerbation.  
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MATERIALS AND METHODS  
STUDY POPULATION: 
This study was conducted in 50 adults (both male and female) 
admitted to Government Rajaji Hospital, Madurai with signs and 
symptoms of acute exacerbation of COPD. 
INCLUSION CRITERIA: 
Patients admitted with acute exacerbation of COPD. 
EXCLUSION CRITERIA: 
¾ Pulmonary embolism 
¾ Renal failure 
¾ Myocardial infarction 
¾ Persistent hemodynamic instability requiring inotropic (or) 
vasoactive support. 
¾ History of cardiac surgery 
¾ History of cardiac resuscitation before admission. 
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DATA COLLECTION: 
Informed written consent obtained. 
Basic demographic data, history and symptoms recorded. 
Co-morbidities like obesity, hypertension, ischemic heart disease, 
previous myocardial infarction, atrial fibrillation, and diabetes mellitus 
were noted. Tobacco users categorized as current, former (>1 year 
abstinence) or non smokers. 
Detailed physical examination including General physical 
Examination and systemic examination was done on each patient. 
Glasgow Coma Score was also calculated for each case. 
Each patient was subjected to arterial blood gas analysis, chest    
X-ray, Electrocardiogram (ECG), Echocardiography, spirometry in 
patients who were able to perform it, and other routine 
blood/biochemical investigations. 
The following were also recorded: Length of hospital stay, 
including stay in ICU and duration of ventilator support, if any in-
hospital mortality rate. 
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Blood samples for cTnT will be measured on admission and 24 
hours later using quantitative assay by ELISA method. Levels above 
0.017µg/l were taken as positive. 
LABORATORY INVESTIGATIONS : 
Each patient was subjected to ABG analysis, chest X-ray, ECG, 
ECHO, Spirometry and blood for Troponin T, routine and biochemical 
investigations.  
STUDY PROTOCOL 
DESIGN OF STUDY : A prospective Study.  
PERIOD OF STUDY: August 2014 to October 2014.  
COLLABORATING DEPARTMENTS : 
Department of Medicine  
Department of Thoracic Medicine  
Department of Biochemistry. 
Department of Cardiology. 
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ETHICAL CLEARANCE : Obtained. 
CONSENT : Individual written and informed consent.  
ANALYSIS : Statistical Analysis.  
CONFLICT OF INTEREST : Nil 
FINANCIAL SUPPORT : Nil 
SAMPLE SIZE: 50 patients with acute exacerbation of COPD admitted 
in Government Rajaji Hospital, Madurai.  
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RESULTS AND INTERPRETATION 
50 patients who met the inclusion and exclusion criteria were 
included in the study. Among them 46 were males and 4 were females. 
 
Table 2: Gender distribution of patients studied. 
Gender No. of patients % 
Female 4 8.0 
Male 46 92.0 
Total 50 100.0 
 
Graph 1: showing gender distribution of the study population. 
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Table 3: Tobacco Use in the patients studied. 
 
Tobacco use No. of patients % 
   Current            29             58.0 
   Former           17            34.0 
   Non smoker            4             8.0 
   Total          50         100.0 
 
Graph 2: Showing division of patients according to their status of 
Tobacco use.  
 
 
 
 
 
58% of the patients were current smokers, 34% were former 
smokers and only 4 % were non-smokers among the patients studied. 
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Table 4:  Showing various presenting complaints in the study 
population 
 
Symptom No. of patients % 
Breathlessness 50 100 
Cough with increased/ changed 
sputum 
29 58 
Fever 13 26 
Swelling of lower limbs 7 14 
Altered sensorium 2 4 
 
 
Presenting symptoms: 
All patients presented with acute onset of increased breathlessness. 
58% had cough with increased amount (or) altered quality of sputum. 
Fever was one of the presenting complaints in 26% patients. 14% patients 
had swelling of lower limbs. Altered sensorium due to carbon dioxide 
narcosis was found in 4%. 
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Table 5: Patient groups according to their cTnT level. 
Troponin No. of patients % 
Positive (Group 1) 19 38.0 
Negative (Group 2) 31 62.0 
Total 50 100.0 
 
Graph 3: showing division of patients into 2 groups, cTnT positive 
and negative. 
 
cTnT was found to be positive in 19 patients and negative in 31 
patients. Accordingly they were divided into two groups, group1 
included patients with cTnT positive and group 2 with cTnT negative. 
cTnT Positive
cTnT negative
38%
62%
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Table 6: Age distribution of patients according to cTnT levels. 
Age in years 
cTnT +ve 
(>0.017 µg/dl) 
n=19 
cTnT –ve 
(<0.017µg/dl) 
n=31 
Total (%) 
50-60 8(42.1%) 9(29%) 17(34%) 
61-70 7(36.8%) 15(48.4%) 22(44%) 
71-80 4(21.1%) 6(19.4%) 10(20%) 
>80 0(0%) 1(3.2%) 1(2%) 
Total 19(100%) 31(100%) 50(100%) 
 
Graph 4 : Showing age distribution of patients according to  cTnT 
levels. 
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Age: 
Patients’ age ranged from 55 to 95 yrs. 42% of patients in group 1 
were in their 6thdecade, where as in the negative group, 48.5% were in 
their 7th decade. 
However mean age did not significantly differ among the 2 groups, 
it was 64.1 yrs in the positive group and 66.72 yrs in the negative group. 
Table 7: Time from onset of Symptoms according to cTnT levels. 
Time from 
onset of 
Symptoms 
cTnT +ve 
(>0.017 µg/dl) 
n=19 
cTnT –ve 
(<0.017µg/dl) 
n=31 
Total  
< 1day 0 2 2 
1-3 days 9 6 15 
4-7 days 5 11 16 
> 7 days 5 12 17 
Total 19 31 50 
 
The time between onset of symptoms to presentation to hospital in 
majority of patients was 1 to 3 days in group 1, whereas it was > 7 days in 
group 2 as shown in the graph below. 
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Graph 5: showing time interval between onset of symptoms to 
presentation to hospital among the 2 groups. 
 
 
Mean duration of COPD in group 1 was 6.42 yrs, where as in group 2 
it was 3.97 yrs. Co morbidities such as Hypertension, Diabetes are 
more prevalent in patients in group 1 when compared between both 
groups. 
Patients in both groups were tachypnoiec, had tachycardia and no 
significant difference was found between them. Mean blood pressure also 
did not significantly differ among the 2 groups. 
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However when comparing patients with or without cTropT 
elevation, difference was found for SpO2, mean SpO2 in cTnT positive 
group was 75% and in cTnT negative group, it was 82.29%, which is 
significant difference. 
There was no significant difference in findings on systemic 
examination and Glasgow Coma Score among the patients in both groups. 
These baseline characteristics of patients in both groups is 
compared and shown in the table below. 
Table 8: Base Line Characteristics of patients on admission 
according to level of cTnT 
 
Variables 
cTnT +ve 
(>0.017µg/dl) 
n=19 
cTnT –ve 
(<0.017µg/dl) 
n=31 
P Value 
Trop T (µg/L) 0.272 <0.01  
Age 64.15±7.75 66.72±8.62 0.286 
Males 17(89.5%) 29(93.5%) 0.606 
Females 2(10.5%) 2(6.5%) 0.606 
Current Smokers 9(47.4%) 20(64.5%) 0.232 
Disease Duration 
(Years) 6.42±3.34 3.97±1.94 0.002** 
Co Morbidity 10(52.6%) 8(25.8%) 0.055+ 
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HTN 6(31.6%) 5(16.1%) 0.201 
DM 5(26.3%) 5(16.1%) 0.382 
Clinical Features 
RR 31.79±4.61 30.32±4.90 0.299 
HR 108.32±12.42 103.94±11.76 0.217 
SBP 123.47±22.91 128.13±16.99 0.415 
SpO2 75.00±11.44 82.29±4.86 0.003** 
Rhonchi 17(89.5%) 30(96.8%) 0.291 
Crackles 13(68.4%) 18(58.1%) 0.464 
Silent Chest 6(31.6%) 4(12.9%) 0.109 
GCS 
<6.0 1(5.3%) 0 0.388 
 6-9 2(10.5%) 1(3.2%) 0.549 
>9 16(84.2%) 30(96.7%) 0.147 
Table 9: Cardiovascular characteristics of patients according to 
level of cTnT 
Variables 
cTnT +ve 
(>0.017 µg/dl) 
n=19 
cTnT –ve 
(<0.017µg/dl) 
n=31 
P Value 
ECG 
Sinus tachycardia 14(73.7%) 24(77.42%) 0.764 
P Pulmonale 6(31.5%) 14(45.16%) 0.341 
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Sinus tachycardia was the most common finding on ECG in both 
the groups, followed by P pulmonale which was seen on ECG in 31.5% 
of patients with elevated cTnT and 45.2% with cTnT negative.  
Table 10: comparing ECHO characteristics of patients in both 
groups. 
Variables 
cTnT +ve 
(>0.017µg/dl) 
n=19 
cTnT –ve 
(<0.017µg/dl) 
n=31 
P Value 
PASP mmHg 
Normal < 30 2(10.5%) 3(9.6%) 0.914 
Mild 31-45 7(36.8%) 15(48.4%) 0.218 
Moderate 45-59 4(21.05%) 7(22.5%) 0.859 
Severe >60 6(31.59%) 6(19.5%) 0.326 
Dilated RA/RV 12 (63.15%) 10(32.25%) 0.033* 
 
Graph 6: showing distribution of patients according to their PASP 
level. 
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On 2D echocardiography, the pulmonary artery systolic pressure 
(PASP) at rest was high in about 90% patients in both groups. However 
severe pulmonary hypertension was found in 31.5% of patients with cTnT 
elevated as compared to 19.5% of patients without elevated cTnT. 
Dilated right heart chambers were found in 63.15% patients in 
group 1 Vs 32.25% patients in group 2. 
 
Graph-7 showing percentage of patients with abnormal blood gases 
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Blood Gases: 
PaO2 was low (i.e<80 mmHg) in 73.7 % patients in group 1 and 
67.7% in group 2. PaCO2 was found to be high (i.e> 45mmHg) in 52.6% 
in group 1 and 45.1% in group 2. 
Table 11: Comparing blood gases according to level of cTnT 
 
Variables 
cTnT +ve 
(>0.017 µg/dl) 
n=19 
cTnT –ve 
(<0.017µg/dl) 
n=31 
P Value 
PaO2 mmHg 78.07±46.05 76.77±32.69 0.907 
PaCo2 mmHg 54.76±24.19 47.77±23.29 0.315 
 
The mean value for these variables also did not differ significantly 
among the two groups. 
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Table 12: Admission to ICU, Need for ventilation, Length of Stay 
and Mortality of patients according to level of cTnT 
Variables 
cTnT +ve 
(>0.017 µg/dl) 
n=19 
cTnT –ve 
(<0.017µg/dl) 
n=31 
P Value 
Admitted to ICU 18(94.7%) 16(51.6%) 0.002** 
NIV/ invasive 15(78.9%) 12(38.7%) 0.006** 
Duration of 
ventilator support 
(median) 4.0 4.0 1.000 
Length of stay in days 
In ICU 5.26±2.28 2.81±4.72 0.019 
In hospital 8.94±4.46 5.80±3.911 0.012 
Mortality 3(15.8%) 2(6.5%) 0.285 
Graph 8: comparing the need for ICU admission, ventilator support 
among both the groups. 
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Graph 9: Showing mean duration ICU & hospital stay in days 
 
 
94.7% needed admission to ICU in the group with elevated cTnT, 
whereas only 51.6% required ICU admission in those without cTnT 
elevation. 
78.9% and 38.7% patients required ventilator support, including 
both noninvasive and invasive ventilation, among the two groups 
respectively. However no significant difference was found in the duration 
of ventilator support required. 
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 Significant difference was found in the length of ICU stay and 
hospital stay between two groups. 
 
Mortality: 
Total of 5 patients died in the study population, three in the 1st group 
and two in the 2nd group. 
No significant difference was found in the in-hospital mortality rate 
between the two groups. 
Chest X ray PA view of a patient, hyperaerated lung fields suggestive of 
COPD 
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ECHO of a patient showing dilated right heart chambers with Pulmonary 
Hypertension, moderate TR and reduced RV function. 
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CT and HRCT images: a) representation of centrilobular emphysema. b) 
representation of panlobular emphysema. c) HRCT scan of a patient with 
emphysema, with predominant paraseptal lesions. d) HRCT of a patient 
with irregular emphysema, with some areas of ‘scar related’emphysema.
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Statistical Methods:  
Descriptive and inferential statistical analysis has been carried 
out in the present study. Results on continuous measurements are 
presented on Mean ± SD (Min-Max) and results on categorical 
measurements are presented in Number (%). Significance is assessed at 
5 % level of significance. 
Student t test (two tailed, independent) has been used to find the 
significance of study parameters on continuous scale between two 
groups. Chi-square/ Fisher Exact test has been used to find the 
significance of study parameters on categorical scale between two or 
more groups. 
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DISCUSSION 
Among the 50 patients included in this study, cTnT was found 
to be elevated in 19 patients, which corresponds 38%. 
 
This suggests that cardiac injury exists in patients with 
exacerbation of COPD. 
This finding that elevated cardiac troponins occurs in patients with 
acute exacerbation of COPD is consistent with many studies 
described, although incidence of cTnT elevation has been different as 
shown in the table below. 
 
Table 13: comparing the incidence of elevated troponin in patients 
with acute exacerbation in various studies with present study. 
 
Author and year of 
publication 
Incidence of cardiac 
troponin elevation 
Baillard et al,200353 18% 
Martins et al,200954 70% 
Hoiseth et al,201156 74% 
Brekke et al,200957 27% 
Chang et al,201158 16.6% 
Present study 38% 
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There was a significant co-relation with the duration of the disease; 
patients with elevated cTnT had longer duration. 
 
Elevated cTnT was also associated with higher prevalence of 
severe pulmonary hypertension and corpulmonale.  
Previous studies have reported higher incidence of ventilator 
support, poor prognosis and increased mortality in patients with 
elevated cardiac troponin during acute exacerbation of COPD. A 
study by Baillard et al also showed elevation of cardiac troponins in 
patients with acute severe exacerbation of COPD was an independent 
predictor of mortality. Similarly Hoiseth et al showed that elevated hs-
cTnT was associated with higher mortality. 
 
Martin et al showed that patients with elevated cardiac troponins 
had longer hospital stay with greater need for non-invasive ventilation 
and lower 18 month survival. 
 
In agreement to other studies, in this study there was a strong         
co-relation with elevated cTnT and need for admission to ICU and 
ventilator support, as well as  ICU stay or hospital stay duration were 
statistically significant when compared between the two groups. 
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It was also not a strong predictor of in hospital mortality as shown 
by few studies. 
 
 Mortality was longer in patients with elevated cardiac 
troponins when compared to those without troponin elevation among 
the studies mentioned below, even if it was not statistically significant. 
 
Table 14: Showing percentage for ventilator support, hospital stay 
and mortality in patients with elevated cardiac troponins in 
various studies. 
 
Study Need for 
Ventilator 
Hospital stay Mortality 
Baillard et al 46% - 62% 
Martins et al 45% 10days 7.6% 
Hoiseth et al - - 58.3% per 100 
patient yrs 
Chang et al - - 14.3% 
Present study 78.9% 8.94days 15.8% 
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Graph 10: comparing mortality rate in patients with elevated 
cardiac troponin in different studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The above findings suggest that cardiac injury exists in patients 
with exacerbation of COPD. However the exact mechanism for 
elevation of cTnT in acute exacerbation of COPD was not within the 
scope of this study, but it being an enzyme specific for cardiac muscle 
injury the reasons for its elevation that could be proposed are:                                        
i. Worsening of pulmonary hypertension, RV pressure overload 
ii. Hypoxemia, and hypercapnia 
iii. Oxidative stress 
iv. Increased work of breathing  
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v. Inflammation(both local and systemic) 
vi. Increased left ventricular afterload due to more negative 
intrathoracic pressure 
 
From prognostic point of view this is an important observation, 
as we can identify a subgroup of patients at particular risk. When proper 
cause for elevation is identified, we may actually be picking a subset 
of patients earlier and if treated appropriately it will influence the long 
term outcome. 
 
LIMITATIONS: 
 
Due to severe dyspnoea and hypoxia in some of the patients, 
ABG at the time of admission could not be drawn at room air in them. 
 
This study did not include follow up, hence the long term 
outcome associated with cTnT elevation could not be evaluated. 
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CONCLUSION: 
• cTnT is elevated in a significant subset of patients with acute 
exacerbation of COPD. 
• These patients had significantly longer duration of COPD, 
higher incidence of lower SpO2. 
• It was an independent predictor of need for ICU admission 
and ventilator support. 
• Significant difference in length of stay in ICU or hospital was 
found between both groups. 
• It did not predict in-hospital mortality. 
• Thus it can be used as a marker to identify patients at higher 
risk at the time of admission. 
• Further studies involving larger number of patients are 
recommended to evaluate whether long term outcome varies in 
patients with elevated cTnT. 
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SUMMARY 
50 Patients with acute exacerbation of COPD were studied from 
August 2014 to October 2014. A male preponderance was found with 
M:F ratio being 11.5:1. 58% were current smokers and 34% were former 
smokers. 
 All patients (100%) presented with increase breathlessness of 
varying duration. 58% of patients had  cough with increased or change 
in the character of sputum. 
19(38%) of the 50 patients were found to have elevated cTnT 
and were included in group 1, the rest form group 2. Mean age of 
patients in group1 was 64.1 years and it was 66.72 years in                   
group 2. Mean age in each group did not differ significantly between two 
groups.  
Mean duration of COPD was 6.42 years in group 1 vs 3.97 years 
in group 2, which is significant difference.  
 Their mean SPO2 was also lower compared to patients without 
elevation of cTnT. Mean SpO2 was 75% in cTnT elevated group and it 
was 82.29% in group 2.                                                     
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Comorbid conditions like diabetes and hypertension were more 
prevalent in group 1 than in group 2, but they were not correlated 
significantly. 
Comparing the ECHO features of the two groups 31.59% of the 
patients had severe pulmonary hypertension in group 1, whereas only 
19.5% in group 2. RA and RV dilatation was significantly higher in 
group 1. 
 PaO2 was low and PaCO2 was high in larger percentage of 
patients in group 1 compared to those in group 2. But mean value of these 
variables did not differ significantly between two groups. 
cTnT elevation significantly correlated with ICU admission, 
need for ventilation, duration of stay in  ICU and hospital stay duration. 
94.7% of patients required ICU admission in group 1 whereas 51.6% 
needed admission to ICU in group 2. 78.9% and 38.7% of patients 
needed mechanical ventilation among two groups respectively. 
 Although mortality was higher in group 1, it was not statistically 
significant. Thus cTnT can be taken as a marker to identify high 
risk patients during acute exacerbation of COPD. 
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 PROFORMA: 
CARDIAC TROPONIN T IN PATIENTS WITH ACUTE 
EXACERBATION OF COPD 
Case No: 
Name: 
IP No: 
Age: 
Sex: 
Address: 
Occupation : 
DOA : 
DOD : 
Tobacco Use : 
Current smoker 
 
Former smoker  
(> 1yr of abstinence) 
Never 
 
   
 
Chief Complaints: 
 Co Morbidities: 
Co morbidity Yes No 
Obesity   
Hypertension   
Diabetes mellitus   
IHD   
Previous MI   
Atrial fibrillation   
 
 
 
Significant past history: 
Family history: 
On examination: 
Pallor Icterus Cyanosis Clubbing Lymphadeno Pedal 
      
 
 
Heart rate: 
Temperature: 
Respiratory rate: 
Blood Pressure: 
 SpO2 : 
RS: Inspection: 
 
Palpation: 
Percussion: 
Auscultation: 
Rhonchi   
Crepitations   
Silent chest   
Other findings   
 
 
Other systems:  
CVS: 
Abdomen: 
CNS: 
Glasgow Coma Score: <6 6 – 9 >9 
    
 
 Chest X Ray: 
ECG: 
ECHO: 
ABG: 
 TC DC ESR 
 B. Urea Sr.Creatinine 
 Cardiac Troponin T : 
On admission 24 Hrs later
  
 
PEFR: 
Spirometry(dated) : FEV1/FVC = 
Diagnosis: 
Length of ICU stay: 
No. of days on ventilator: 
Hospital stay: 
Outcome: 
 LIST OF ABBREVIATIONS USED 
CAT: COPD assessment test 
COPD: Chronic Obstructive Pulmonary Disease 
CHF: Congestive Heart Failure 
CRP: C-reactive protein 
cTnT: Cardiac Troponin T 
DM: Diabetes Mellitus 
ECG: Electrocardiogram 
ECHO: Echocardiography 
FEV1: Forced Expiratory Volume in one second 
FVC: Forced Vital Capacity 
GCS: Glasgow Coma Scale 
GOLD: Global Initiative for Chronic Obstructive Lung Disease 
HTN: Hypertension 
HR: Heart Rate 
ICU: Intensive Care Unit 
IHD: Ischemic Heart Disease 
LV: Left Ventricle 
LVD: Left Ventricular Dysfunction 
mMRC: modified Medical Research Council 
NT-proBNP: N-terminal pro-brain natriuretic peptide 
PH: Pulmonary Hypertension 
PaCO2: Partial Pressure of CO2 in arterial blood 
PaO2: Partial Pressure of Oxygen in arterial blood 
PASP: Pulmonary Artery Systolic Pressure 
MI: Myocardial Infarction 
NIV: Non-invasive ventilation 
RA: Right Atrium 
RV: Right Ventricle 
RR: Respiratory Rate 
SBP: Systolic Blood Pressure 
SD: Standard Deviation 
SNS: Sympathetic Nervous System 
WHO: World Health Organization 
                       
 
  
S.NO AGE SEX SMOKE Co-MOR DURATION R.RATE PULSE SPO2 Rh CR S GCS X-RAY PASP 
mmHg 
CHAMBERS 
1 65 M F HT,DM 12 28 112 78 P P A 15 COPD 39 NORMAL 
2 75 M C DM 10 30 106 60 P P A 15  COPD,LLZ 37 NORMAL 
3 70 F N DM 7 34 110 82 P A P 15 COPD 35 RA,RVD 
4 80 M C NIL 10 36 120 71 P A P 15 COPD 76 RA,RVD 
5 60 M C NIL 4 34 104 78 P P A 15 COPD,BL 44 NORMAL 
6 50 M F NIL 8 40 112 80 A A P 15 COPD 24 NORMAL 
7 65 F N DM 5 32 110 56 P P A 6 COPD,LLZ 46 RA,RVD 
8 56 M C NIL 5 38 134 76 P A P 7 COPD 60 RA,RVD 
9 55 M C NIL 3 28 116 80 P P A 15 COPD.RLZ 46 RA,RVD 
10 60 M C NIL 2 28 98 80 P P A 15 COPD 72 RA,RVD 
11 60 M F NIL 5 32 112 76 P P A 15 COPD,RLZ 84 RA,RVD 
12 65 M F HT 6 34 112 78 P P A 15 COPD,M 41 NORMAL 
13 55 M F HT,DM 6 26 112 84 P P A 15 COPD,PHT 61 NORMAL 
14 73 M F NIL 5 34 106 74 P P A 14 COPD 57 RA,RVD 
15 65 M F HT 2 40 110 82 P P A 15 COPD 77 RA,RVD 
16 73 M F HT 15 28 78 88 P A P 15 COPD,PHT 37 RA,RVD 
17 68 M C NIL 6 24 82 40 A P P 4 COPD 27 RA,RVD 
18 64 M C DM 6 30 106 82 P P A 15 COPD,RLZ 55 RA,RVD 
19 60 M C HT,DM 5 28 118 80 P A A 15 COPD 36 NORMAL 
   cTnT +Ve Master Chart 
  
S.NO ECG PaCO2 PaO2 cTnT(1) cTnT(2) PEFR FEVI/FVC VENTI ICU HOSP OUTCOME 
1 ST,P.PUL 26.5 66.9 0.01 0.3 <60 0.49 8 9 19 DISCHARGE 
2 ST 33.5 46.7 0.01 0.19 80 0.53 0 5 8 DISCHARGE 
3 ST 34.5 59.2 0.035 0.023 70 0.48 3 5 7 DISCHARGE 
4 ST 48.3 59.3 0.026 0.014 70 0.57 3 3 4 DISCHARGE 
5 ST 87.5 87.5 0.047 0.068 60 0.48 7 7 7 DISCHARGE 
6 ST 74.9 33.4 0.22 0.051 60 0.04 3 4 4 DISCHARGE 
7 ST 41.4 56.5 0.032 0.059 <60 0.52 4 6 10 DISCHARGE 
8 ST,P.PUL 78.4 97.3 0.033 0.052 <60 UTP 4 4 4 DEATH 
9 ST 58.2 47.7 0.022 0.01 <60 0.4 6 8 11 DISCHARGE 
10 P.PUL 60.3 61 0.056 0.091 60 UTP 6 6 6 DEATH 
11 RAD,P.PUL 27 62 0.27 0.01 60 0.6 5 6 12 DISCHARGE 
12 ST 45 184.8 0.9 2.2 70 0.57 0 7 14 DISCHARGE 
13 P.PUL 42.1 63.6 0.041 0.061 60 0.45 0 0 5 DISCHARGE 
14 ST 38.6 55.3 0.59 0.44 60 0.56 4 4 4 DEATH 
15 ST,P.PUL 26.4 59.1 0.4 0.2  0.54 5 6 15 DISCHARGE 
16 RAD 54.3 57.3 1.2 0.58 60 UTP 3 9 15 DISCHARGE 
17 NORMAL 115 214.9 0.022 0.021 <60 0.7 5 5 6 DISCHARGE 
18 ST 79.7 96 0.09 0.022 <60 0.36 3 4 11 DISCHARGE 
19 ST 68.6 74.9 0.16 1.1 <60 0.58 0 2 8 DISCHARGE 
  
 
                                                                                                      cTnT –ve Master Chart 
S.NO AGE SEX SMOKE Co-MOR DURATION R.RATE PULSE SPO2 Rh CR S GCS X-RAY PASP 
mmHg 
CHAMBERS 
1 56 M C NIL 2 36 130 78 P A P 15 COPD 37 NORMAL 
2 65 M C NIL 4 30 114 82 P P A 15 COPD,RL 60 RA,RVD 
3 62 M C NIL 5 32 96 82 P A A 15 COPD 36 NORMAL 
4 55 M C NIL 2 30 120 78 P P A 15 COPD,LLZ 37 NORMAL 
5 56 M F NIL 5 32 102 84 P A A 15 COPD 36 NORMAL 
6 70 M F NIL 3 28 96 88 P P A 15 COPD 46 NORMAL 
7 80 M F NIL 3 24 90 84 P A A 15 COPD 36 NORMAL 
8 73 F F NIL 3 26 100 90 P P A 15 COPD 56 RA,RVD 
9 75 M N HT 5 40 96 70 P P A 8 COPD,RLZ 38 RA,RVD 
10 80 M C NIL 3 26 88 80 P P A 15 COPD,MZ 60 NORMAL 
11 66 M C NIL 10 38 100 82 P P A 15 COPD,LLZ 36 NORMAL 
12 65 M C DM,HT 2 36 102 80 A A P 15 COPD,RLZ 24 NORMAL 
13 65 M C NIL 2 22 90 86 P P A 15 COPD 36 NORMAL 
14 70 M C HT 2 36 94 84 P A A 15 COPD 37 NORMAL 
15 60 M F NIL 5 34 94 82 P P A 13 COPD 70 RA,RVD 
16 65 M C NIL 3 40 106 80 P A A 5 COPD 36 NORMAL 
17 64 M C NIL 2 30 120 80 P P A 15 COPD 36 NORMAL 
18 60 F C NIL 5 32 108 78 P A P 15 COPD,PHT 56 RA,RVD 
19 65 M N OBESITY 4 28 106 79 P P A 15 COPD 45 RA,RVD 
20 68 M C NIL 6 24 98 86 P P A 15 COPD 28 NORMAL 
21 55 M C HT,DM 4 32 130 85 P P A 15 COPD 43 NORMAL 
22 65 M C HT,DM 4 26 100 80 P P A 15 COPD,B/L 60 RA,RVD 
23 60 M F HT,DM 2 26 98 88 P P A 15 COPD 32 LVH 
24 77 M F HT,DM 3 30 130 88 P P A 15 COPD 45 ASH 
25 65 M C DM 5 36 112 84 P P A 15 COPD 47 RA,RVD 
26 70 M C NIL 3 28 96 86 P A A 15 COPD 60 RA,RVD 
27 70 M C NIL 5 26 100 90 P A A 15 COPD 49 NORMAL 
28 60 M F NIL 9 32 110 69 P P A 15 COPD 70 RA,RVD 
29 95 M C NIL 6 24 98 80 P A P 11 COPD,PHT 40 NORMAL 
30 60 M F NIL 3 30 104 84 P A A 15 COPD 30 NORMAL 
31 73 M C NIL 3 26 94 84 P A A 15 COPD 40 NORMAL 
 
 
 
 S.NO ECG PaCO2 PaO2 cTnT(1) cTnT(2) PEFR FEVI/FVC VENTI ICU HOSP OUTCOME 
1 ST,P.PUL 27 91 <0.01 <0.01 60 0.5 0 0 3 DISCHARGE 
2 ST,P.PUL 53 34 <0.01 <0.01 60 0.5 4 5 6 DISCHARGE 
3 ST,P.PUL 50 56 <0.01 <0.01 60 0.3 0 0 5 DISCHARGE 
4 ST 25 60 <0.01 <0.01 80 0.7 0 0 5 DISCHARGE 
5 ST,P.PUL 33 78 0.01 0 100 0.5 4 4 7 DISCHARGE 
6 ST 27 53 <0.01 <0.01 60 0.4 0 0 4 DISCHARGE 
7 NORMAL 50 72 <0.01 <0.01 70 0.6 4 5 7 DISCHARGE 
8 ST,P.PUL 41 39 <0.01 <0.01 80 0.4 0 0 3 DISCHARGE 
9 P.PUL 42 75 0.014 0 NA NA 4 4 4 DEATH 
10 ST,P.PUL 26 61 <0.01 <0.01 60 0.5 5 5 9 DISCHARGE 
11 ST 34 65 <0.01 <0.01 60 NA 8 9 9 DEATH 
12 ST 38 58 <0.01 <0.01 NA NA 25 25 25 DISCHARGE 
13 NORMAL 40 50 <0.01 <0.01 120 0.5 0 0 5 DISCHARGE 
14 ST,P.PUL 30 66 <0.01 <0.01 100 0.5 0 0 4 DISCHARGE 
15 ST,P.PUL 52 72 <0.01 0 90 0.6 3 3 5 DISCHARGE 
16 ST 37 50 <0.01 <0.01 100 0.4 0 0 5 DISCHARGE 
17 ST 27 58 0.016 <0.01 70 0.6 0 0 4 DISCHARGE 
18 ST,RAD 52 67 <0.01 <0.01 60 0.6 3 3 6 DISCHARGE 
19 ST,RAD 59 77 <0.01 <0.01 <60 0.6 0 3 5 DISCHARGE 
20 ST 51 68 <0.01 <0.01 70 0.7 0 0 4 DISCHARGE 
21 ST,P.PUL 41 63 <0.01 <0.01 60 0.6 0 0 5 DISCHARGE 
22 INV V4-V6 59 45 <0.01 <0.01 60 0.5 0 2 4 DISCHARGE 
23 NORMAL 26 79 <0.01 <0.01 70 NA 0 0 3 DISCHARGE 
24 ST,LAD 28 63 <0.01 <0.01 80 NA 0 5 6 DISCHARGE 
25 ST,RAD 45 68 <0.01 <0.01 70 0.6 0 6 7 DISCHARGE 
26 ST,RAD 60 88 <0.01 <0.01 70 0.4 4 4 7 DISCHARGE 
27 ST 39 86 <0.10 <0.01 NA NA 4 5 7 DISCHARGE 
28 RAD,MAT 61 97 0.015 0 <60 0.6 0 0 3 DISCHARGE 
29         ST 61 88 <0.01 <0.01 70 0.4 1 1 4 DISCHARGE 
30 ST,P.PUL 47 87 <0.01 <0.01 70 0.4 0 0 5 DISCHARGE 
31 ST 55 89 <0.01 <0.01 65 0.7 0 0 4 DISCHARGE 
 
 
 
 
 
 
 
 
 KEY TO MASTER CHART: 
C- current smoker 
F- former smoker 
N- non smoker 
M- Male 
F- Female 
B - breathlessness 
C&E - cough and expectoration 
E- pedal edema 
HTN- hypertension 
DM- diabetes mellitus 
RR- Respiratory rate 
HR- heart rate 
SBP- systolic BP 
Rh- rhonchi 
CR- crepitations 
S- silent chest 
R- Right 
L- Left 
UZ- Upper Aone 
Lz- Lower Zone 
Con- Consolidation 
 PH- Pulmonary Hypertension 
RA - right atrium 
RV- right ventricle 
DIL – dilated 
ST - sinus tachycardia 
P.pul-  P. pulmonale 
RAD - Right axis deviation 
UTP - Unable to Perform 
NIV - Non invasive Ventilation 
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